Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Interleukin 2, Aldesleukin and Entinostat for Kidney Cancer
This study is currently recruiting participants.
Verified April 2013
by National Cancer Institute (NCI)
Study NCT01038778 Information provided by National Cancer Institute (NCI)
First Received on December 18, 2009. Last Updated on April 9, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Renal Cell
More general conditions related to this trial
Adenocarcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
entinostat
aldesleukin
pharmacological study
laboratory biomarker analysis
fludeoxyglucose F 18
positron emission tomography
computed tomography
Additional drug interventions recognized in this trial
Histone Deacetylase Inhibitors
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
